NCT07804056 A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer
| NCT ID | NCT07804056 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Hamlet Pharma AB |
| Condition | Urinary Bladder Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 194 participants |
| Start Date | 2026-09-17 |
| Primary Completion | 2029-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 194 participants in total. It began in 2026-09-17 with a primary completion date of 2029-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if the drug Alpha1H works to treat low-to-intermediate risk non-muscle-invasive bladder cancer in adults. It will also learn about the safety of drug Alpha1H. The main questions it aims to answer are: * Does giving drug Alpha1H before surgery lower the risk of cancer returning or worsening compared to standard care alone? * Is drug Alpha1H safe and well-tolerated by participants? Researchers will compare participants receiving drug Alpha1H before standard surgery to participants receiving standard care alone to see if drug Alpha1H lowers the risk of cancer returning or progressing. Participants will: * Be randomly assigned to receive either drug Alpha1H before surgery or standard care alone. * Receive drug Alpha1H directly into the bladder 6 times over about 1 month if assigned to the Alpha1H group. * Hold the liquid in the bladder for up to 2 hours during each visit. * Undergo standard surgery through the urethra (TURBT) to remove remaining tumor tissue. * Visit the clinic regularly for follow-up checkups (including bladder examinations and urine tests) to check if the cancer returns. * Fill out questionnaires about their quality of life.
Eligibility Criteria
Inclusion Criteria: * Signed and dated informed consent. * Low- or intermediate-risk non-muscle-invasive bladder cancer (NMIBC) meeting one of the following definitions: * Low-risk NMIBC: Primary, solitary, Ta, low-grade, 0.5 cm to 3 cm. * Intermediate-risk NMIBC (low-to-intermediate risk subgroup per IBCG classification): * Primary multifocal (\<10 lesions), Ta, low-grade, 0.5 cm to 3 cm; * Recurrent solitary, Ta, low-grade, 0.5 cm to 3 cm; or * Recurrent multifocal (\<10 lesions), Ta, low-grade, \>1 year after previous recurrence. * Men and women aged 18 years or older. * Negative pregnancy test at screening for women of childbearing potential. * Women of childbearing potential must agree to use highly effective contraception methods throughout study participation; men of childbearing potential must refrain from donating sperm during the study. * Ability to retain bladder contents for 2 hours. Exclusion Criteria: * Patient with non-papillary tumor appearance at the time of initial cystoscopy. * Previous history of T1 or high-grade disease in recurrent tumors. * Patients with T1 or high-grade non-muscle invasive papillary bladder cancer (NMIBC). * Previous intravesical BCG immunotherapy. * Patients with any other cancer diagnosis within the last 5 years (except for skin basalioma). * Acute urinary tract infection requiring antibiotic treatment. * Prior radiotherapy or systemic chemotherapy. * WHO performance status of 3 or 4. * Any other investigational agent or non-marketed product within one month prior to Visit 1 and during the trial. * Known active HIV infection, defined as detectable HIV viral load at screening. * Active hepatitis B virus (HBV) infection, defined as hepatitis B surface antigen (HBsAg) positivity with detectable HBV DNA at screening. * Active hepatitis C virus (HCV) infection, defined as anti-HCV antibody positivity with detectable HCV RNA at screening in a patient not on stable antiviral treatment. * Any concurrent illness that may render a participant ineligible or limit compliance with study requirements. * Previously enrolled in this trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07804056 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urinary Bladder Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07804056 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 194 participants.
Is NCT07804056 currently recruiting?
Yes, NCT07804056 is actively recruiting participants. Contact the research team at catharina.svanborg@med.lu.se for enrollment information.
Where is the NCT07804056 trial being conducted?
This trial is being conducted at Prague, Czechia.
Who is sponsoring the NCT07804056 clinical trial?
NCT07804056 is sponsored by Hamlet Pharma AB. The trial plans to enroll 194 participants.